Abstract Library

#3259 Treatment outcomes of patients with G3 neuroendocrine neoplasms

Introduction: Extrapulmonary neuroendocrine carcinomas (NEC) and neuroendocrine tumors (NET) G3 are aggressive neoplasia that are associated with a limited prognosis.

Conference: 18th Annual ENETS Concerence (2021)

Presenting Author: Roderburg C

Authors: Jann H, Wiedenmann B, Tacke F, Roderburg C,

Keywords: NEN G3, chemotherapy, Cisplatin, Carboplatin,

#3232 Treatment outcomes of patients with G3 neuroendocrine neoplasms - Data from the German NET Registry

Introduction: NEN G3 comprise a heterogeneous group of rare aggressive neoplasm with few established treatment options.

Conference: 18th Annual ENETS Concerence (2021)

Presenting Author: Luecke S

Authors: Luecke S, Fottner C, Lahner H, Jann H, Zolnowski D,

Keywords: NEN G3, NEC, NET, Ki67, prognosis, chemotherapy,

#3080 Impact of Multimodal Perioperative Treatment in Patients with Resected Non-Metastatic Grade 3 Neuroendocrine Neoplasms (NEN G3)

Introduction: Patients with grade 3 neuroendocrine neoplasm (NEN G3) have a limited prognosis. Even in a non-metastatic stage, the risk of recurrence after surgery is high. Multimodal perioperative treatment, including chemotherapy and/or radiotherapy in an adjuvant or neoadjuvant setting, has improved the prognosis in numerous tumor entities; however, it has not been systematically evaluated in NEN G3 so far. Nevertheless, perioperative chemotherapy is generally recommended in most current treatment guidelines for NEN G3.

Conference: 17th Annual ENETSConcerence (2020)

Presenting Author:

Authors: Apostolidis L, Starke H, Bhatti I, Jäger D, Winkler E,

Keywords: NEN G3, neuroendocrine carcinoma, adjuvant, neoadjuvant, surgery,

#2991 Gastroenteropancreatic (GEP) Neuroendocrine Neoplasia G3 (NEN G3) According to 2019 WHO Classification: A Comprehensive Clinicopathological Characterization Including Mismatch Repair (MMR) Proteins, PDL1 Expression and KRAS/BRAF Status

Introduction: In the 2019 WHO FOR NEN’S classification NETG3 have been distinguished from poorly differentiated neuroendocrine carcinoma (NEC). They are heterogeneous group concerning prognosis and treatment benefit.

Conference: 17th Annual ENETSConcerence (2020)

Presenting Author:

Authors: Ruiz G, Graselli J, Golubicki M, Rizzol M,

Keywords: G3 NEN, PD-L1, KRAS, BIOMARKERS,

#2936 Mutational Landscape of 109 High-Grade Gastroenteropancreatic Neuroendocrine Neoplasms G3

Introduction: Gastroenteropancreatic (GEP) neuroendocrine neoplasms (NEN) G3 are rare with a poor outcome. Molecular data for GEP NEN G3 is limited and the 2019 WHO classification is based on morphology and proliferation rate.

Conference: 17th Annual ENETSConcerence (2020)

Presenting Author: Elvebakken H

Authors: Venizelos A, Elvebakken H, Perren A, Hjortland G, Sundlöv A,

Keywords: molecular genetics, neuroendocrine carcinoma, neuroendocrine tumors, gastroenteropancreatic, mutations,